We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,
Australasia,Asia,Middle East,Africa
Monthly Production Capacity: hundreds of grams
Packaging Information: 500mg,1g, 10g,50g 100g per package with icebag
Delivery Lead Time: In stock or 2-3weeks
Sample Provided: yes
Payment Terms: T/T
Human antimicrobial peptide LL-37 has strong antibacterial and anti-inflammatory activity, broad-spectrum antibacterial effect number, but due to its relatively large molecular weight, and low cell selectivity in the body, coupled with high production costs, it limits LL -37 Application in treatment. Therefore, a new short α-helical antimicrobial peptide derived from LL-37 was developed. This type of antimicrobial peptide with a shorter sequence has better cell selectivity, and compared with LL-37, its anti-inflammatory activity is not significantly lost. LL-37 FK-13 is one of the short α-helix antimicrobial peptides derived from LL-37. It consists of 13 amino acids and has high cell selectivity and anti-inflammatory activity. Studies have shown that LL-37 FK-13 can kill microbial cells by penetrating the cell membrane and destroying the integrity of the membrane.
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
